anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Echinacoside (ECH) is a prominent naturally occurring bioactive compound with effects of alleviating myocardial damage. We aimed to explore the beneficial effects of ECH against sepsis-induced myocardial damage and elucidate the potential mechanism. Echocardiography and Masson staining demonstrated that ECH alleviates cardiac function and fibrosis in the cecal ligation and puncture (CLP) model. Transcriptome profiling and network pharmacology analysis showed that there are 51 overlapping targets between sepsis-induced myocardial damage and ECH. Subsequently, chemical carcinogenesis-reactive oxygen species (ROS) were enriched in multiple targets. Wherein, SOD2 may be the potential target of ECH on sepsis-induced myocardial damage. Polymerase chain reaction results showed that ECH administration could markedly increase the expression of SOD2 and reduce the release of ROS. Combined with injecting the inhibitor of SOD2, the beneficial effect of ECH on mortality, cardiac function, and fibrosis was eliminated, and release of ROS was increased after inhibiting SOD2. ECH significantly alleviated myocardial damage in septic mice, and the therapeutic mechanism of ECH is achieved by upregulating SOD2 which decreased the release of ROS.
This is a pilot open-label trial of 25 RA patients treated with tofacitinib over 3 months. The patients meeting inclusion criteria will be started on tofacitinib 5mg po bid. Patients will be recruited from the UCLA Rheumatology Clinics. Inclusion criteria will include the following: meeting ACR 1987 RA criteria, DAS28≥3.2, age≥18, and PDUS\>10 (see below for more details). Patients who are deemed unsafe to enroll will be excluded. Ultrasound measures (PDUS/GSUS) and MBDA scores will be obtained at screen, baseline, 2 weeks, and 3 months. In addition, we will also obtain HAQ-DI, CDAI, and DAS28 at the same time points. In addition, we will have a 6 week visit for capturing adverse events, concomitant drugs, drug dispensation, and evaluation of adherence. Currently, there are several US measures to evaluate therapeutic response in RA patients that have been used in the literature. Some US studies evaluate all joints involved in RA, which is time consuming. At present, there is no consensus as to the ideal ultrasound scoring system. However, we will utilize a 34-joint US scoring system to evaluate response to therapy in this proposal (see Table 1). Our research team has expertise in MSUS (given several workshops/lectures nationally) and we have proficiency in designing/conducting MSUS clinical trials. We currently have 4 ultrasonography-rheumatologists at UCLA who are ACR certified in MSUS.
Alzheimer's disease (AD) is linked to toxic Aβ plaques in the brain and activation of innate responses. Recent findings however suggest that the disease may also depend on the adaptive immunity, as B cells exacerbate and CD8+ T cells limit AD-like pathology in mouse models of amyloidosis. Here, by artificially blocking or augmenting CD8+ T cells in the brain of 5xFAD mice, we provide evidence that AD-like pathology is promoted by pathogenic, proinflammatory cytokines and exhaustion markers expressing CXCR6+ CD39+CD73+/- CD8+ TRM-like cells. The CD8+ T cells appear to act by targeting disease associated microglia (DAM), as we find them in tight complexes with microglia around Aβ plaques in the brain of mice and humans with AD. We also report that these CD8+ T cells are induced by B cells in the periphery, further underscoring the pathogenic importance of the adaptive immunity in AD. We propose that CD8+ T cells and B cells should be considered as therapeutic targets for control of AD, as their ablation at the onset of AD is sufficient to decrease CD8+ T cells in the brain and block the amyloidosis-linked neurodegeneration.
ABBOTT ESA Chagas testing will be performed at a minimum of two blood donor centers. Testing will be performed using the FDA-licensed ESA Chagas assay and will be performed in accordance with the ESA Chagas package insert. ABBOTT PRISM Chagas repeatedly reactive blood donor specimens identified by U.S. blood donor centers, as part of the routine blood donation process, will be tested with the FDA-licensed ESA Chagas. Specimens will also be tested with radioimmune precipitation assay (RIPA) for antibody to T. cruzi, a laboratory developed test, and the FDA-licensed ORTHO T. cruzi ELISA. The donor centers will contact the donors and request the donor to return to complete a questionnaire and provide a follow-up specimen.

In addition, a minimum of 300 blood donor specimens with ABBOTT PRISM Chagas nonreactive results will also be tested with ESA Chagas. These specimens will be unidentified, leftover specimens from routine donor testing and not individually identifiable. Specimens that are positive or indeterminate with ESA Chagas will be further tested with RIPA.
A virtual reality neuropsychological assessment (VRNA) system uses a deep learning network and a VR headset to administer multi-domain assessments of human cognitive performance. The deep learning network is trained to identify features in sensor data indicative of neuropsychological performance and classify users based on the features identified in the sensor data. The VR headset provides a user with a virtual simulation of an activity involving decision-making scenarios. During the virtual simulation, sensor data via a plurality of sensors of the VR headset is captured. The sensor data is applied to the deep learning network to identify features of the user and classify the user based on the features into a neuropsychological domains, such as attention, memory, processing speed, and executive function. Sensor data includes eye-tracking, hand-eye motor coordination, reaction time, working memory, learning and delayed memory, and inhibitory control.
The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.
Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
Unique abrasive and/or thickening materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial characteristics depending on the structure of the composite in situ generated material. With low structured composites (as measured via linseed oil absorption levels from 40 to 100 ml oil absorbed/100g composite), simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels are possible in order to accord the user a dentifrice that effectively cleans tooth surfaces without detrimentally abrading such surfaces. Increased amounts of high structure composite materials tend to accord greater viscosity build and thickening benefits together with such desirable abrasion and cleaning properties, albeit to a lesser extent than for the low structure types.  Thus, mid-range cleaning materials will exhibit oil absorption levels from an excess of 100 to 150, and high thickening/low abrasion composite exhibit oil absorption properties in excess of 150. Such an in situ, simultaneously produced precipitated silica/silica gel combination provides such unexpectedly effective low abrasion and high cleaning capability and different thickening characteristics as compared to physical mixtures of such components. Encompassed within this invention is a unique method for making such gel/precipitated silica composite materials for such a purpose, as well as the different materials within the structure ranges described above and dentifrices comprising such.
Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
The present invention discloses medicine for resisting tuberculosis and a preparation method of the medicine, which is characterized in that the ingredients of the medicine are cantharide powder, induced protein and an excipient. 1.9512% of the cantharide powder 97.56% of the induced protein and 0.04878% of the excipient are taken, the cantharide powder is poured in the induced protein., and after the cantharide powder and the induced protein are stirred evenly, the cantharide powder and the induced protein are steamed, cooked, cooled and confricated. After the cantharide powder and the induced protein are dried or solarized, the cantharide powder and the induced protein are pulverized and sieved, and finally, the excipient is poured inside; sticking juice is taken and is made into granules, the cantharide powder and the induced protein are dried or dried in the sun, and the medicine for resisting the tuberculosis is formed. The medicine of the present invention is mainly used for treating tubercular diseases, such as phthisis, lymphoid tuberculosis, tuberculosis of spine, pulmonary tuberculosis, etc. After the medicine of the present invention is taken for 10 to 15 days, the phthisis inside and outside the lung is cured, phlegm smears of original phthisis patients with yang bacteria are negative, and focus smears of other kinds of the patients are changed into a negative state from a positive state. The medicine of the present invention has the advantages of no toxic and side effect, short treatment course and low expense. The present invention is a great creation in traditional Chinese medicine and brings positive use effect to extensive patients with tuberulosises.
Sleeping metabolic rate will be measured using a metabolic chamber on the night of day 2. During day 3, 24-hour energy expenditure (including a second night of measurement) will be measured in the metabolic chamber. On this day, the participant will perform 2 bouts of physical activity on a stationary bicycle for 15 minutes each bout. This will give us a measurement of physical activity energy expenditure. On day 4, at 7 am, the participant will exit the metabolic chamber and will enter a different, smaller metabolic chamber for the measurement of energy expenditure in response to a meal. This measurement will start at approximately 8 am with assessment of the resting metabolic rate (45 minutes). The participant will then be given a high-fat meal replacement to consume over 10 minutes. Energy expenditure measurements continue in the metabolic chamber for a 6-hour period.
Regimen B: docetaxel 75 mg/m\^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
OBJECTIVE: In this study, we established a Sprague-Dawley rat model of vulvar squamous intraepithelial lesions and investigated the impact of focused ultrasound on the expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and mutant type p53 (mtp53) in the vulvar skin of rats with low-grade squamous intraepithelial lesions (LSIL).
MATERIALS AND METHODS: The vulvar skin of 60 rats was treated with dimethylbenzanthracene (DMBA) and mechanical irritation three times a week for 14 weeks. Rats with LSIL were randomly allocated into the experimental group or the control group. The experimental group was treated with focused ultrasound, while the control group received sham treatment.
RESULTS: After 14 weeks treatment of DMBA combined with mechanical irritation, LSIL were observed in 44 (73.33%) rats, and high-grade squamous intraepithelial lesions (HSIL) were observed in 14 (23.33%) rats. 90.91% (20/22) of rats showed normal pathology and 9.09% (2/22) of rats exhibited LSIL in the experimental group at four weeks after focused ultrasound treatment. 22.73% (5/22) of rats exhibited LSIL, 77.27% (17/22) of rats progressed to HSIL in the control group. Compared with the control-group rats, the levels of HIF-1α, VEGF and mtp53 were significantly decreased in experimental-group rats (p < 0.05).
CONCLUSIONS: These results indicate that DMBA combined with mechanical irritation can induce vulvar squamous intraepithelial lesion in SD rats. Focused ultrasound can treat LSIL safely and effectively, prevent the progression of vulvar lesions, and improve the microenvironment of vulvar tissues by decreasing the localized expression of HIF-1α, VEGF, and mtp53 in rats.
With a constant increase in prevalence and incidence worldwide, stroke remains a public health issue in the 21st century. Additionally, population aging inevitably leads to increased vulnerability in the general population, a clinical state known as frailty. While there are adequate guidelines on the treatment of stroke in the acute setting, there are a lot of gaps regarding the chronic management of stroke patients, particularly the frail ones. From the therapeutic point of view, palliative care could be the key to offering complex and individualized treatment to these frail chronic stroke patients. In the context of the heterogeneous data and incomplete therapeutic guidelines, this article provides a new and original perspective on the topic, aiming to increase awareness and understanding and improve palliative care management in stroke patients. Based on current knowledge, the authors describe a new concept called the frailty-stroke continuum and offer a detailed explanation of the intricate stroke-frailty connection in the first part. After understanding the role of palliative care in managing this kind of patients, the authors discuss the most relevant practical aspects aiming to offer an individualized framework for daily clinical practice. The novel approach consists of developing a four-step scale for characterizing frail stroke patients, with the final aim of providing personalized treatment and correctly evaluating prognosis. By pointing out the limitations of current guidelines and the challenges of new research directions, this article opens the pathway for the better evaluation of frail stroke patients, offering a better perception of patients' prognosis.
A method for inhibiting the secretion of stomach acid in vertebrate animals. The method comprises contacting the lumen side of the stomach with a compound which interferes with the acid secretion mechanism yet cannot permeate the lining of the stomach. The compound has a molecular weight of less than 1,200 and at least ten percent of the molecular weight of the compound is due to the molecular weight contribution of secondary amine nitrogen. The invention also includes an ingestible product for inhibiting the secretion of stomach acid in vertebrate animals. The product is ingested so that it is contacted with the lumen side of the stomach to interfere with the acid secretion mechanism without permeating the lining of the stomach. The product contains a compound which has a molecular weight of less than 1200, at least ten percent of the molecular weight of the compound being due to the molecular weight contribution of secondary amine nitrogen. The product is in the form of a solution, dispersion, capsule or tablet.
The invention relates to a multienzyme delivery nanoparticle, a preparation method and application thereof, and belongs to the technical field of medicines. The nano-composite provided by the invention is formed by grafting polyethylene glycol and alpha-bromoisobutyryl onto polyallylamine, and then forming a network polymer outside a protein polymer coacervate core through a polymerization reaction at room temperature. The obtained nanoparticles have long-circulating property in vivo and biocompatibility. The beneficial effects are as follows: nanoparticles allow efficient transport of substrates and final metabolites while leaving the coacervate unfixed by the porous polymer network after the formation of the coacervate on the outer layer of the enzyme. Upon transport of the substrate into the nanoparticle, the enzymes in the core form a substrate channeling effect due to the close proximity of the coacervates to each other, minimizing diffusion of intermediates between the enzymes, thereby improving overall reaction efficiency and specificity. At the same time, the polymer shell improves the stability of the enzyme under physiological conditions.
Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
PURPOSE:To obtain the titled substance useful as an antineoplastic agent, from the cultured product obtained by culturing bacteria belonging to Gliocladium genus, Chaetomium genus or Trichoderma genus and capable of producing the titled substance. CONSTITUTION:Bacteria belonging to Gliocladium genus, Chaetomium genus or Trichoderma genus and capable of producing gliocladic acid, e.g. Gliocladium virens SANK12679 strain, Chaetomium globosum SANK13379 strain, Trichoderma viride SANK13479 strain, etc. are cultured in a medium containing dextrin, glucose, soybean flour, peptone, yeast, inorganic salt, etc. under aeration and agitation at 20-30 deg.C and weakly acidic or neutral conditions for 45-90hr. The cultured liquid is filtered, and the objective gliocladic acid is separated from the filtrate by using an adsorbent, etc.
This was a six-cohort, multicenter, prospective study planned for up to 88 relapsing multiple sclerosis (MS) participants. The study was intended to address two questions: 1) Can participants treated with ofatumumab develop an immune response if receiving a COVID-19 mRNA vaccine two weeks prior to ofatumumab start? 2) If receiving COVID-19 mRNA vaccine after introduction of ofatumumab treatment, can participants develop an immune response? Cohort 1: participants received an mRNA COVID-19 vaccine at least two weeks prior to ofatumumab start. Cohort 2: participants received an mRNA COVID-19 vaccine at least four weeks after beginning ofatumumab. Cohort 3: participants on an interferon or glatiramer acetate who received COVID-19 mRNA vaccine. Cohort 4: participants fully vaccinated with an RNA COVID-19 vaccine at least four weeks after ofatumumab start. Cohort 5: participants vaccinated with an RNA COVID-19 vaccine, with or without a booster dose, and on interferon or glatiramer acetate. Cohort 6: participants fully vaccinated with an RNA COVID-19 vaccine who received a booster dose at least four weeks after ofatumumab start. Participants obtained the COVID-19 mRNA vaccine from their HCP (private insurance) or appropriate federal, state or local program.

Participants in Cohort 1 received loading doses of ofatumumab and subsequent dosing was 20 mg s.c. administered monthly. All other cohorts continued current dosing schedule of either ofatumumab, glatiramer acetate or interferon. Participation in trial was maximum of 421 days which was dependent on the Cohort.
INTRODUCTION: Advances in haemophilia treatment have resulted in a near-normal life expectancy, lower burden of bleeding and treatment, and improved quality of life in high-income countries. Bleeding rate is approaching zero and novel parameters should be evaluated to assess the efficacy of treatment not only from the clinical point of view by using new methodologies (e.g. joint health assessment), but also from the patient's perspective (e.g. pain, quality of life, treatment satisfaction).
METHODS AND RESULTS: This approach should be aimed at combining objective clinical methodologies and patient-reported outcomes (PROs). However, some instruments used for assessing PROs are still suboptimal and not properly validated. Recent evidence suggests that these tools can take advantage from a more personalized designed approach and could be effectively improved and serve to facilitate the patient's self-evaluation. For other congenital bleeding disorders (BDs), a set of patient-relevant outcomes has been also defined that overlap substantially those of haemophilia, including bleeding, side effects and complications, and PROs, such as pain, physical functioning, impact on daily life including school and work and mental health. There is a growing focus on addressing women-specific outcomes in BDs, reflecting an increased awareness of the unique challenges faced by women in this context. However, the development of tailored tools is imperative to further advance the progress in managing women with BDs, ensuring more accurate monitoring and personalized care.
CONCLUSIONS: How incorporating these outcome measures in the process of approval of novel treatments for these disorders by regulatory authorities remains to be established.
ABSTRACT OF THE DISCLOSURE         Platinum-olefinic hydrocarbon complexes, e.g.  platinum-styrene complexes are prepared by reacting a platinum halide with styrene or ring-substituted styrenes in the presence of a basic material for a sufficient amount of time to form a platinum-olefinic hydrocarbon, e.g. platinum-styrene, complex having more than one and less than four gram atoms of halogen per gram atom of platinum.  These platinum-olefinic hydrocarbon, e.g. platinum-styrene complexes may be used to promote the addition of organosilicon compounds having at least one   SiH group per molecule to a compound containing aliphatic unsaturation.  Thus, the above described complex may be used   in a process for the addi-tion of an organosilicon compound containing silicon-bonded hydrogen to an organic compound having carbon-carbon unsaturation which comprises forming a mixture containing the organosilicon compound having silicon-bonded hydrogen and an organic compound having carbon-carbon unsaturation.          It has been found that a very small amount of the catalyst will effect the desired reaction between the silicon-bonded hydrogen compound and the unsaturated organic compound.  In addition, it has been found that the catalyst retains its level of activity even after storing for pro-longed periods of time at elevated temperatures.  Furthermore, the activity of the catalyst is such that silicon-bonded hydrogen containing organopolysiloxanes and vinyl containing-organopolysiloxanes can be cured very rapidly and therefore used as potting or encapsulating compositions for electrical components on assembly lines,
Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.